This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol. 2005; 56:91-6.10.1007/s00280-004-0924-915791461SendoTSakaiNItohYIkesueHKobayashiHHirakawaTet alIncidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy20055691615791461Open DOISearch in Google Scholar
Taxol injection (package insert). Princeton: Bristol-Myers Squibb Company; 2007.PrincetonBristol-Myers Squibb Company2007Search in Google Scholar
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358: 1663-71.1842049910.1056/NEJMoa0707056SparanoJAWangMMartinoSJonesVPerezEASaphnerTet alWeekly paclitaxel in the adjuvant treatment of breast cancer2008358166371274394318420499Search in Google Scholar
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-76.10.1056/NEJMoa07211318160686MillerKWangMGralowJDicklerMCobleighMPerezEAet alPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer200735726667618160686Open DOISearch in Google Scholar
Köppler H, Heymanns J, Weide R. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie. 2001; 24:283-5. [Article in English, German]KöpplerHHeymannsJWeideRDose reduction of steroid premedication for paclitaxelOnkologie200124[Article in English, German]10.1159/00005509311455223Search in Google Scholar
Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2012; 20:1991-7.10.1007/s00520-011-1303-922089428BergerMJDunleaLJRettigAELustbergMBPhillipsGSShapiroCLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction20122019917341129922089428Open DOISearch in Google Scholar
Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, et al. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015; 23:2019-24.2551975610.1007/s00520-014-2556-xBergerMJVargoCVincentMShaverKPhillipsGLaymanRet alStopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction201523201924480433925519756Search in Google Scholar
Piovano E, Pivetta E, Modaffari P, Martra F, Baima Poma C, Perotto S, et al. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest. 2012; 74: 21-7.10.1159/00033677222652565PiovanoEPivettaEModaffariPMartraFBaimaPoma CPerottoSet alA search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms20127421722652565Open DOISearch in Google Scholar
Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efûcacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer. 2006; 119:712-7.10.1002/ijc.2174316496381SuiMChenFChenZFanWGlucocorticoids interfere with therapeutic efûcacy of paclitaxel against human breast and ovarian xenograft tumors2006119712716496381Open DOISearch in Google Scholar
Hou WJ, Guan JH, Dong Q, Han YH, Zhang R. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice. Eur Rev Med Pharmacol Sci. 2013; 17:2902-8.24254559HouWJGuanJHDongQHanYHZhangRDexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice20131729028Search in Google Scholar